Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Revenue per Share : $1.23 (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Revenue per Share?

Aurinia Pharmaceuticals's revenue per share for the three months ended in Dec. 2023 was $0.31. Aurinia Pharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.23.

Warning Sign:

Aurinia Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of Aurinia Pharmaceuticals was 29.80% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 42.50% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 257.40% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 55.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Aurinia Pharmaceuticals's Revenue per Share or its related term are showing as below:

AUPH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -84.1 Med: -10.6 Max: 580.2
Current: 42.5

During the past 13 years, Aurinia Pharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 580.20% per year. The lowest was -84.10% per year. And the median was -10.60% per year.

AUPH's 3-Year Revenue Growth Rate is ranked better than
81.76% of 773 companies
in the Biotechnology industry
Industry Median: 5.6 vs AUPH: 42.50

Aurinia Pharmaceuticals Revenue per Share Historical Data

The historical data trend for Aurinia Pharmaceuticals's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Revenue per Share Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

Get a 7-Day Free Trial

0.42

0.35

0.94

1.23

Aurinia Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Revenue per Share	Get a 7-Day Free Trial															0.20	0.24	0.29	0.38	0.31

Competitive Comparison of Aurinia Pharmaceuticals's Revenue per Share

For the Biotechnology subindustry, Aurinia Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurinia Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's PS Ratio falls into.

Aurinia Pharmaceuticals Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Aurinia Pharmaceuticals's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	175.513	/	143.236
	=	1.23

Aurinia Pharmaceuticals's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )	=	Revenue (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	45.095	/	143.689
	=	0.31

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.23

Aurinia Pharmaceuticals (NAS:AUPH) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Aurinia Pharmaceuticals Revenue per Share Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

IKAP:Germany IKAP:Germany

Address

4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Executives

Robert T Foster	director	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
R. Hector Mackay-dunn	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w.	director	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Jill Leversage	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Daniel Billen	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Brinda Balakrishnan	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Peter Greenleaf	director, officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Joseph M Miller	officer: Chief Financial Officer	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Stephen P. Robertson	officer: EVP, General Counsel	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Milne George M Jr	director
Matthew Maxwell Donley	officer: Ex VP, Intern'l Operations	4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Scott Michael Habig	officer: Chief Commercial Officer	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8